Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Nitazoxanide

FDA-approved product (tablet, oral), marketed as Alinia, Nitazoxanide.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Nitazoxanide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Amebiasis
  • Diarrhea

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other agents against amoebiasis and other protozoal diseases
FDA pharmacologic class
Antiprotozoal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P01AX11; FDA class Antiprotozoal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA36.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli33.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae15.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis77.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 1 of 1 lab record
Open Nitazoxanide in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nitazoxanide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Nitazoxanide for the Treatment of Prolonged Diarrhea in Children

    NCT01326338 · start 2005-03

    Registered record
    Registry ID
    NCT01326338
    Conditions
    Diarrhea
    Interventions
    Nitazoxanide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-03
    Completion
    2006-05
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiarrhea
    InterventionNitazoxanide
    PhasePhase 3
    Registry statusCompleted

  • Study of Nitazoxanide in the Treatment of Amebiasis in Adults and Adolescents

    NCT00366236 · start 2004-02

    Registered record
    Registry ID
    NCT00366236
    Conditions
    Amebiasis
    Interventions
    Nitazoxanide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-02
    Completion
    2005-11
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmebiasis
    InterventionNitazoxanide
    PhasePhase 3
    Registry statusCompleted

  • Safety and Effectiveness of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients

    NCT00004986 · start 2000-02

    Registered record
    Registry ID
    NCT00004986
    Conditions
    Cryptosporidiosis; HIV Infections
    Interventions
    Nitazoxanide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2000-02
    Completion
    Not recorded
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCryptosporidiosis; HIV Infections
    InterventionNitazoxanide
    PhasePhase 3
    Registry statusTerminated

  • A Study of Nitazoxanide in Patients With AIDS and Diarrhea Caused by Cryptosporidium

    NCT00001081

    Registered record
    Registry ID
    NCT00001081
    Conditions
    Cryptosporidiosis; HIV Infections
    Interventions
    Nitazoxanide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1998-09
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCryptosporidiosis; HIV Infections
    InterventionNitazoxanide
    PhasePhase 2
    Registry statusCompleted

  • Nitazoxanide for the Treatment of Chronic Diarrhea in HIV Infected Children

    NCT00055107

    Registered record
    Registry ID
    NCT00055107
    Conditions
    HIV Infections; Cryptosporidiosis
    Interventions
    Nitazoxanide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2006-05
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Cryptosporidiosis
    InterventionNitazoxanide
    PhasePhase 1 / Phase 2
    Registry statusCompleted